Driver mutations in lung cancer

Due to an increasing comprehension of the molecular basis of carcinogenesis it has become apparent that the known forms of lung cancer so far (non-small cell lung cancer (NSCLC) with its main subgroups adenocarcinoma and squamous cell carcinoma and small cell lung cancer (SCLC)) consist of numerous subgroups. These subgroups are characterized by molecular changes (mutations, translocations, amplifications, i.a.). Since these changes are responsible for the malignant growth of the tumor cells, they are called driver mutations. More and more of these driver mutations are discovered, allowing a targeted therapy that is more effective and better tolerated than conventional chemotherapy.

More information

Last update: 17. March 2016 , 8:51

Molecular diagnostics

As the first group in Europe, the Network Genomic Medicine has offered a comprehensive analysis of tumor material since 2012. By means of a multiplex-test in combination with highly sensitive deep sequencing even rare gene mutations in the smallest tissue samples are detected reliably

Second opinion

Do you have questions about your disease or your current therapy? Or maybe you would like to know if for you a personalized treatment approach or immunotherapy might be considered. Please feel free to contact us!

Clinical trials

At the Network Genomic Medicine we try to offer an appropriate clinical trial testing a new drug to all our patients who have a detected mutation, for which there has no drug been approved for treatment yet. For that we work closely together with the Lung Cancer Group Cologne.

Share This